Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care.

J Acquir Immune Defic Syndr

*Division of Research, Kaiser Permanente Northern California, Oakland, CA; †Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA; ‡Kaiser Permanente San Leandro Medical Center, Kaiser Permanente Northern California, San Leandro, CA; §Department of Research and Evaluation, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; and ‖Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic, Rockville, MD.

Published: September 2016

Background: It is unknown if a survival gap remains between HIV-infected and HIV-uninfected individuals with access to care.

Methods: We conducted a cohort study within Kaiser Permanente California during 1996-2011, using abridged life tables to estimate the expected years of life remaining ("life expectancy") at age 20.

Results: Among 24,768 HIV-infected and 257,600 HIV-uninfected individuals, there were 2229 and 4970 deaths, with mortality rates of 1827 and 326 per 100,000 person-years, respectively. In 1996-1997, life expectancies at age 20 for HIV-infected and HIV-uninfected individuals were 19.1 and 63.4 years, respectively, corresponding with a gap of 44.3 years (95% confidence interval: 38.4 to 50.2). Life expectancy at age 20 for HIV-infected individuals increased to 47.1 years in 2008 and 53.1 years by 2011, narrowing the gap to 11.8 years (8.9-14.8 years) in 2011. In 2008-2011, life expectancies at age 20 for HIV-infected individuals ranged from a low of 45.8 years for blacks and 46.0 years for those with a history of injection drug use to a high of 52.2 years for Hispanics. HIV-infected individuals who initiated antiretroviral therapy with CD4 ≥500 cells per microliter had a life expectancy at age 20 of 54.5 years in 2008-2011, narrowing the gap relative to HIV-uninfected individuals to 7.9 years (5.1-10.6 years). For these HIV-infected individuals, the gap narrowed further in subgroups with no history of hepatitis B or C infection, smoking, drug/alcohol abuse, or any of these risk factors.

Conclusions: Even with early treatment and access to care, an 8-year gap in life expectancy remains for HIV-infected compared with HIV-uninfected individuals.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427712PMC
http://dx.doi.org/10.1097/QAI.0000000000001014DOI Listing

Publication Analysis

Top Keywords

hiv-uninfected individuals
24
life expectancy
16
hiv-infected individuals
16
years
13
narrowing gap
12
hiv-infected hiv-uninfected
12
age hiv-infected
12
individuals
10
hiv-infected
9
life
8

Similar Publications

Background: Nutritional risk assessment is an essential component of primary health care screening, especially for pregnant women. The aim of this study was to investigate the relationship between maternal body mass index (BMI) and maternal anthropometric measurements in black South African pregnant women, both with and without human immunodeficiency virus (HIV).

Materials And Methods: A cross-sectional observational study design was used.

View Article and Find Full Text PDF

Background: People living with HIV (PLHIV) demonstrate accelerated aging and immunosenescence in spite of immune-restoration following long-term antiretroviral treatment (ART). Low level inflammation leading to inflammaging plays an important role in mediating premature immunosenescence. Ongoing viral replication, antiretrovirals and subclinical infections with the common viruses like Cytomegalovirus (CMV) are known to induce inflammaging.

View Article and Find Full Text PDF

Innate-immune cell distribution in pediatric HIV patients and uninfected controls.

Rev Inst Med Trop Sao Paulo

December 2024

Universidade do Estado do Rio de Janeiro, Departamento de Microbiologia, Imunologia e Parasitologia, Rio de Janeiro, Rio de Janeiro, Brazil.

Innate immune cells are important players during an infection. The frequency of monocytes, myeloid-derived suppressor cells (MDSCs), natural killer (NK), and NKT cells were assessed in blood samples of children and adolescents living with HIV (CALHIV) and HIV-uninfected (HU) children. Blood samples from 10 CALHIV (treated or not) and six HU individuals were collected for approximately one year.

View Article and Find Full Text PDF

The human immunodeficiency virus (HIV), a retrovirus targeting the immune system and the primary agent causing acquired immunodeficiency syndrome (AIDS), can have fatal consequences. Although antiretroviral treatment has significantly reduced mortality and comorbidity in people living with HIV (PLHIV), its impact on metabolic syndrome (MetS) remains notable. Several genome-wide association studies have identified a link between the gene () and MetS, particularly in type 2 diabetes.

View Article and Find Full Text PDF

Background: High-grade resistance to sulfadoxine-pyrimethamine in East and Southern Africa has prompted numerous trials evaluating intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine as an alternative to sulfadoxine-pyrimethamine.

Methods: We conducted individual participant data meta-analyses of randomised trials comparing IPTp with dihydroartemisinin-piperaquine to sulfadoxine-pyrimethamine on maternal, birth, and infant outcomes. We searched the WHO International Clinical Trials Registry Platform, ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!